MAP2K7 and cancer: Recently, BI-3406, a SOS1–KRAS interaction inhibitor, was shown to attenuate SOS1 dependent feedback reactivation induced by MEK inhibitors and thereby enhance sensitivity of KRAS-dependent cancers to MEK inhibition [34].